To All Brothers & Sisters

"A Blessed & Happy New Year "

"May we have a good year ahead"

Best Wishes & Warmest Regards

from

MalaysianKidneySPA

Reader's comment....

We have received with thanks a comment from our reader:


"Heparin is a wonderful drug of course, however problems with Heparin Induced Thrombocytopenia, overanticoagulation with bleeding and clotting due to underanticoagulation exist. The main issue is that one size or dose in this case does not fit all and dosing of heparin ought to be guided by aCT monitoring. But this is expensive and beyond the reach of most stand alone centres. Another alternative is to use low molecular weight heparins, but only the porcine versions have predictable dose responses. Other alternatives exist but are not readily available in the country.....Yudi" 


Yes Yudi we agree with you that low molecular weight heparin is a much better alternative, unless and until someone introduce the bovine version and at a affordable price, we have no choice but to do with what we have.....MalaysianKidneySPA

To All Christian Brothers & Sisters

"A Blessed and Merry Christmas"

"Joy to the World"

Best Wishes & Warmest Regards

from

MalaysianKidneySPA

What is....

CONTINUOUS RENAL REPLACEMENT THERAPY (CRRT)

Dr. Manish Chaturvedi Nephrologist, Dr. S. N. Medical College, Jodhpur

The Indian Anaesthetists’ Forum – (www.theiaforum.org) Online ISSN 0973-0311 October 2004

It is a mode of renal replacement therapy for hemodynamically unstable, fluid overloaded, catabolic septic patients and finds its application in management of acute renal failure especially in the critical care /intensive care unit setting. The popularity of ‘slow continuous therapies’ for the treatment of critically ill patients with renal failure is increasing. The techniques most commonly used are slow continuous hemodialysis and hemodiafiltration. Slow continuous hemofiltration and slow continuous ultrafiltration also are commonly used.

ARF in the ICU setting is frequent especially secondary to multiple organ dysfunction syndrome; post surgical setting i.e after abdominal surgery; post interventional studies eg. PTCA, PTRA studies in already susceptible individuals. These patients having various co-morbid conditions are on mechanical ventilation and various life supporting modalities which do not merit the dialysis procedure to be carried out in the routine dialysis set up.

Being catabolic, they require continuous clearance of waste produced due to ongoing illnesses and an adequate potential for infusion of nutritional and inotropic agents for sustenance of vital parameters which is continuously desired in the management. CRRT has tried to meet these challenges in the ICU settings since its inception and has saved many lives across the globe including critically ill paediatric or geriatric population with renal failure as a co-existent co-morbid illness.

The outcome of therapy depends on clearance of waste products achieved with restoration of blood biochemistry; maintenance of fluid, electrolyte and acid base balance; ability to maintain hemodynamic stability during the procedure with minimum side effects during the procedure.

Read more here

The Kidney Project at UCSF

Reader's comment:

Article: Artificial Kidney made by Indian American


"very much thanks to malaysiankidneyspa.blogspot.com for providing such a useful information. 


Dear Dr.Shuvo Roy more than half of the world is praying for your success. Hope very soon your artificial kidney will be available for human being also. very best of luck Dr. Shuvo Roy. Best blessing for you and your family."      


by Aman

Artificial kidney made by Indian American

Artificial kidney made by Indian American awaits human trials

Sifynews 2010-12-03 14:13:2 Submitted by Mr CS Soong

Washington: A coffee cup sized implantable artificial kidney being developed by a US researcher of Indian origin, is awaiting animal and human trials to bring affordable treatment to millions of kidney failure patients worldwide. Shuvo Roy, working with a team of engineers, biologists and physicians at the University of California, San Francisco, to shrink the device to the size of a coffee cup, is "excited about advancing it towards large animal and human trials". "Obviously, a key requirement is financial support and the team. We have most of the latter in place, and the former is a work-in-progress," Roy, an associate professor in the UCSF School of Pharmacy who specialises in developing micro-electromechanical systems (MEMS) technology for biomedical applications, said. "There are almost 1.5 million people worldwide on dialysis. The primary cause of end stage renal disease (ESRD) is diabetes and hypertension, which are both growing problems in South Asia," noted Roy who has a connection with both India and Bangladesh. Read more here